Abstract:Cancer stem cells (CSCs) found within cancer tissue play a pivotal role in its resistance to therapy and its potential to metastasize, contributing to elevated mortality rates among patients. Significant strides in understanding the molecular foundations of CSCs have led to preclinical investigations and clinical trials focused on CSC regulator β-catenin signaling targeted interventions in malignancies. As part of the ongoing advancements in marine-organism-derived compound development, it was observed that among the six analogs of Renieramycin T (RT), a potential lead alkaloid from the blue sponge Xestospongia sp., the compound DH_32, displayed the most robust anti-cancer activity in lung cancer A549, H23, and H292 cells. In various lung cancer cell lines, DH_32 exhibited the highest efficacy, with IC50 values of 4.06 ± 0.24 μM, 2.07 ± 0.11 μM, and 1.46 ± 0.06 μM in A549, H23, and H292 cells, respectively. In contrast, parental RT compounds had IC50 values of 5.76 ± 0.23 μM, 2.93 ± 0.07 μM, and 1.52 ± 0.05 μM in the same order. Furthermore, at a dosage of 25 nM, DH_32 showed a stronger ability to inhibit colony formation compared to the lead compound, RT. DH_32 was capable of inducing apoptosis in lung cancer cells, as demonstrated by increased PARP cleavage and reduced levels of the proapoptotic protein Bcl2. Our discovery confirms that DH_32 treatment of lung cancer cells led to a reduced level of CD133, which is associated with the suppression of stem-cell-related transcription factors like OCT4. Moreover, DH_32 significantly suppressed the ability of tumor spheroids to form compared to the original RT compound. Additionally, DH_32 inhibited CSCs by promoting the degradation of β-catenin through ubiquitin–proteasomal pathways. In computational molecular docking, a high-affinity interaction was observed between DH_32 (grid score = −35.559 kcal/mol) and β-catenin, indicating a stronger binding interaction compared to the reference compound R9Q (grid score = −29.044 kcal/mol). In summary, DH_32, a newly developed derivative of the right-half analog of RT, effectively inhibited the initiation of lung cancer spheroids and the self-renewal of lung cancer cells through the upstream process of β-catenin ubiquitin–proteasomal degradation.

A Synthetic Cantharidin Analog for the Enhancement of Doxorubicin Suppression of Stem Cell-Derived Aggressive Sarcoma

Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells Via Β-Catenin Proteasomal Degradation in Human Lung Cancer

Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS Via Mitochondria-Dependent Pathway.

Synergistic effect of a novel cantharidin analog LB1 with doxorubicin in chemotherapy against hepatocellular carcinoma cells

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Mechanistic Insight Into A Novel Synthetic Cantharidin Analogue In A Leukaemia Model

Apoptotic Activity of a Novel Synthetic Cantharidin Analogue on Hepatoma Cell Lines

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Cantharidin and Norcantharidin Impair Stemness of Pancreatic Cancer Cells by Repressing the Β-Catenin Pathway and Strengthen the Cytotoxicity of Gemcitabine and Erlotinib.

Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A

Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery

Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-Like Cells

A Nanodrug-Enabled Chemosensitization of Cancer Stem Cells Against Tumor Progression and Metastasis

Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo

The Radiotherapy-Sensitization Effect of Cantharidin: Mechanisms Involving Cell Cycle Regulation, Enhanced DNA Damage, and Inhibited DNA Damage Repair

Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.

Enhance Drug Sensitivity of Cancer Stem Cells Using Functionalized Mesoporous Silica Nanoparticles

The Combination of Cantharidin and Antiangiogenic Therapeutics Presents Additive Antitumor Effects Against Pancreatic Cancer

Title : Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells under Hypoxic Conditions Short running title : Synthesis and in vitro effects of CBZ-AAN-Dox